Single User License
INR 136060
Site License
INR 272120
Corporate User License
INR 408180

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Pulmonary Hypertension-Pipeline Review, H1 2015

Pulmonary Hypertension-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Pulmonary Hypertension-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Pulmonary Hypertension-Pipeline Review, H1 2015', provides an overview of the Pulmonary Hypertension's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pulmonary Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Hypertension and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Pulmonary Hypertension

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Pulmonary Hypertension and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Pulmonary Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Pulmonary Hypertension pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Pulmonary Hypertension

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Pulmonary Hypertension pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Pulmonary Hypertension Overview 9

Therapeutics Development 10

Pipeline Products for Pulmonary Hypertension-Overview 10

Pipeline Products for Pulmonary Hypertension-Comparative Analysis 11

Pulmonary Hypertension-Therapeutics under Development by Companies 12

Pulmonary Hypertension-Therapeutics under Investigation by Universities/Institutes 17

Pulmonary Hypertension-Pipeline Products Glance 18

Late Stage Products 18

Clinical Stage Products 19

Early Stage Products 20

Pulmonary Hypertension-Products under Development by Companies 21

Pulmonary Hypertension-Products under Investigation by Universities/Institutes 26

Pulmonary Hypertension-Companies Involved in Therapeutics Development 27

Actelion Ltd 27

APT Therapeutics, Inc. 28

Arena Pharmaceuticals, Inc. 29

Asahi Kasei Pharma Corp. 30

Ascendis Pharma A/S 31

Bayer AG 32

Bial-Portela & Ca, S.A. 33

Biolab Sanus Farmaceutica Ltda. 34

Cardioxyl Pharmaceuticals, Inc. 35

Carolus Therapeutics, Inc. 36

Celladon Corporation 37

Celsion Corporation 38

Corridor Pharmaceuticals Inc. 39

Cytokinetics, Inc. 40

Eli Lilly and Company 41

Gilead Sciences, Inc. 42

HanAll Biopharma Co., Ltd. 43

Hanmi Pharmaceuticals, Co. Ltd. 44

Ikaria Inc. 45

Insmed Incorporated 46

Ironwood Pharmaceuticals, Inc. 47

Lacer, S.A. 48

Longevity Biotech, Inc 49

LTT Bio-Pharma Co., Ltd. 50

Mast Therapeutics, Inc. 51

Mezzion Pharma Co. Ltd. 52

miRagen Therapeutics, Inc. 53

Nippon Shinyaku Co., Ltd. 54

Novartis AG 55

PharmaIN Corporation 56

PhaseBio Pharmaceuticals, Inc. 57

Pluristem Therapeutics Inc. 58

Proteo, Inc. 59

Reata Pharmaceuticals, Inc. 60

RegeneRx Biopharmaceuticals, Inc. 61

Sagene Pharmaceuticals, Inc. 62

Silence Therapeutics plc 63

Sinoxa Pharma GmbH 64

Suda Ltd 65

Therametrics holding AG 66

Toray Industries, Inc. 67

United Therapeutics Corporation 68

Vectura Group plc 69

Vicore Pharma AB 70

Pulmonary Hypertension-Therapeutics Assessment 71

Assessment by Monotherapy Products 71

Assessment by Combination Products 72

Assessment by Target 73

Assessment by Mechanism of Action 77

Assessment by Route of Administration 80

Assessment by Molecule Type 82

Drug Profiles 84

(allopurinol + apocynin)-Drug Profile 84

(chlorthalidone + valsartan)-Drug Profile 85

ACP-009-Drug Profile 86

ambrisentan-Drug Profile 87

Antibody for Cancer and PAH-Drug Profile 89

Antibody for Pulmonary Arterial Hypertension-Drug Profile 90

APT-102-Drug Profile 91

bardoxolone methyl-Drug Profile 93

BAY sGCact-Drug Profile 96

beraprost sodium nanoparticles SR-Drug Profile 97

beraprost sodium SR-Drug Profile 98

BIA-51058-Drug Profile 100

BL-214-Drug Profile 101

bosentan CR-Drug Profile 102

C-122-Drug Profile 103

C-21-Drug Profile 104

C-301-Drug Profile 106

CT-2009-Drug Profile 107

DasKloster-1000-01-Drug Profile 108

Drug for Pulmonary Hypertension-Drug Profile 110

Drug for Pulmonary Hypertension-Drug Profile 111

Elafin-Drug Profile 112

esuberaprost sodium-Drug Profile 115

fasudil-Drug Profile 116

GS-4997-Drug Profile 117

HGP-1207-Drug Profile 118

IK-3001-Drug Profile 119

imatinib mesylate-Drug Profile 120

IW-1973-Drug Profile 122

LA-419-Drug Profile 123

lisuride-Drug Profile 124

macitentan-Drug Profile 126

Mydicar-Drug Profile 129

Oligonucleotide to Inhibit Endothelin-1 for Pulmonary Arterial Hypertension-Drug Profile 131

Oligonucleotide to Inhibit MicroRNA-145 for Pulmonary Arterial Hypertension-Drug Profile 132

PB-1046-Drug Profile 133

PB-1120-Drug Profile 135

Peptide to Antagonize Urotensin-II Receptor for PAH-Drug Profile 136

PGC-VIP-Drug Profile 137

PK-10453-Drug Profile 138

R-190-Drug Profile 139

R-197-Drug Profile 141

ralinepag-Drug Profile 142

RGN-352-Drug Profile 143

riociguat-Drug Profile 145

RNAi Oligonucleotide to Inhibit miR-145 for PAH-Drug Profile 148

selegiline + PDE-5 Inhibitor-Drug Profile 149

selexipag-Drug Profile 150

Small Molecule for Pulmonary Arterial Hypertension-Drug Profile 152

Small Molecule to Antagonize Notch Receptor for Pulmonary Arterial Hypertension and Hypoxia-Drug Profile 153

Small Molecule to Inhibit Arginase for Vascular Dysfunction, PAH and Erectile Dysfunction-Drug Profile 154

Small Molecule to Inhibit Myosin for COPD, Asthma And Pulmonary Arterial Hypertension-Drug Profile 156

Small Molecule to Inhibit Soluble Epoxide Hydrolase for Pulmonary Arterial Hypertension-Drug Profile 157

Small Molecules to Activate ACE2 for Pulmonary Arterial Hypertension-Drug Profile 158

Small Molecules to Antagonize 5-HT1B for Pulmonary Arterial Hypertension-Drug Profile 159

Small Molecules to Inhibit MetAP-II for Oncology, Immunology, Infectious Disease, Cardiovascular and Metabolic Disorders-Drug Profile 160

sodium nitrite-Drug Profile 161

Stem Cell Therapy for Cardiovascular Diseases-Drug Profile 163

SUD-004-Drug Profile 165

Synthetic Peptide to Agonize VPAC2 for Pulmonary Arterial Hypertension-Drug Profile 166

Synthetic Peptide to Inhibit NADPH Oxidase for Pulmonary Hypertension-Drug Profile 167

tadalafil-Drug Profile 168

treprostinil diolamine-Drug Profile 170

TXA-127-Drug Profile 171

udenafil-Drug Profile 173

VR-876-Drug Profile 175

Pulmonary Hypertension-Recent Pipeline Updates 176

Pulmonary Hypertension-Dormant Projects 207

Pulmonary Hypertension-Discontinued Products 210

Pulmonary Hypertension-Product Development Milestones 211

Featured News & Press Releases 211

Appendix 220

Methodology 220

Coverage 220

Secondary Research 220

Primary Research 220

Expert Panel Validation 220

Contact Us 220

Disclaimer 221

List of Tables

Number of Products under Development for Pulmonary Hypertension, H1 2015 15

Number of Products under Development for Pulmonary Hypertension-Comparative Analysis, H1 2015 16

Number of Products under Development by Companies, H1 2015 18

Number of Products under Development by Companies, H1 2015 (Contd..1) 19

Number of Products under Development by Companies, H1 2015 (Contd..2) 20

Number of Products under Development by Companies, H1 2015 (Contd..3) 21

Number of Products under Investigation by Universities/Institutes, H1 2015 22

Comparative Analysis by Late Stage Development, H1 2015 23

Comparative Analysis by Clinical Stage Development, H1 2015 24

Comparative Analysis by Early Stage Development, H1 2015 25

Products under Development by Companies, H1 2015 26

Products under Development by Companies, H1 2015 (Contd..1) 27

Products under Development by Companies, H1 2015 (Contd..2) 28

Products under Development by Companies, H1 2015 (Contd..3) 29

Products under Development by Companies, H1 2015 (Contd..4) 30

Products under Investigation by Universities/Institutes, H1 2015 31

Pulmonary Hypertension-Pipeline by Actelion Ltd, H1 2015 32

Pulmonary Hypertension-Pipeline by APT Therapeutics, Inc., H1 2015 33

Pulmonary Hypertension-Pipeline by Arena Pharmaceuticals, Inc., H1 2015 34

Pulmonary Hypertension-Pipeline by Asahi Kasei Pharma Corp., H1 2015 35

Pulmonary Hypertension-Pipeline by Ascendis Pharma A/S, H1 2015 36

Pulmonary Hypertension-Pipeline by Bayer AG, H1 2015 37

Pulmonary Hypertension-Pipeline by Bial-Portela & Ca, S.A., H1 2015 38

Pulmonary Hypertension-Pipeline by Biolab Sanus Farmaceutica Ltda., H1 2015 39

Pulmonary Hypertension-Pipeline by Cardioxyl Pharmaceuticals, Inc., H1 2015 40

Pulmonary Hypertension-Pipeline by Carolus Therapeutics, Inc., H1 2015 41

Pulmonary Hypertension-Pipeline by Celladon Corporation, H1 2015 42

Pulmonary Hypertension-Pipeline by Celsion Corporation, H1 2015 43

Pulmonary Hypertension-Pipeline by Corridor Pharmaceuticals Inc., H1 2015 44

Pulmonary Hypertension-Pipeline by Cytokinetics, Inc., H1 2015 45

Pulmonary Hypertension-Pipeline by Eli Lilly and Company, H1 2015 46

Pulmonary Hypertension-Pipeline by Gilead Sciences, Inc., H1 2015 47

Pulmonary Hypertension-Pipeline by HanAll Biopharma Co., Ltd., H1 2015 48

Pulmonary Hypertension-Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 49

Pulmonary Hypertension-Pipeline by Ikaria Inc., H1 2015 50

Pulmonary Hypertension-Pipeline by Insmed Incorporated, H1 2015 51

Pulmonary Hypertension-Pipeline by Ironwood Pharmaceuticals, Inc., H1 2015 52

Pulmonary Hypertension-Pipeline by Lacer, S.A., H1 2015 53

Pulmonary Hypertension-Pipeline by Longevity Biotech, Inc, H1 2015 54

Pulmonary Hypertension-Pipeline by LTT Bio-Pharma Co., Ltd., H1 2015 55

Pulmonary Hypertension-Pipeline by Mast Therapeutics, Inc., H1 2015 56

Pulmonary Hypertension-Pipeline by Mezzion Pharma Co. Ltd., H1 2015 57

Pulmonary Hypertension-Pipeline by miRagen Therapeutics, Inc., H1 2015 58

Pulmonary Hypertension-Pipeline by Nippon Shinyaku Co., Ltd., H1 2015 59

Pulmonary Hypertension-Pipeline by Novartis AG, H1 2015 60

Pulmonary Hypertension-Pipeline by PharmaIN Corporation, H1 2015 61

Pulmonary Hypertension-Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2015 62

Pulmonary Hypertension-Pipeline by Pluristem Therapeutics Inc., H1 2015 63

Pulmonary Hypertension-Pipeline by Proteo, Inc., H1 2015 64

Pulmonary Hypertension-Pipeline by Reata Pharmaceuticals, Inc., H1 2015 65

Pulmonary Hypertension-Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2015 66

Pulmonary Hypertension-Pipeline by Sagene Pharmaceuticals, Inc., H1 2015 67

Pulmonary Hypertension-Pipeline by Silence Therapeutics plc, H1 2015 68

Pulmonary Hypertension-Pipeline by Sinoxa Pharma GmbH, H1 2015 69

Pulmonary Hypertension-Pipeline by Suda Ltd, H1 2015 70

Pulmonary Hypertension-Pipeline by Therametrics holding AG, H1 2015 71

Pulmonary Hypertension-Pipeline by Toray Industries, Inc., H1 2015 72

Pulmonary Hypertension-Pipeline by United Therapeutics Corporation, H1 2015 73

Pulmonary Hypertension-Pipeline by Vectura Group plc, H1 2015 74

Pulmonary Hypertension-Pipeline by Vicore Pharma AB, H1 2015 75

Assessment by Monotherapy Products, H1 2015 76

Assessment by Combination Products, H1 2015 77

Number of Products by Stage and Target, H1 2015 79

Number of Products by Stage and Mechanism of Action, H1 2015 83

Number of Products by Stage and Route of Administration, H1 2015 86

Number of Products by Stage and Molecule Type, H1 2015 88

Pulmonary Hypertension Therapeutics-Recent Pipeline Updates, H1 2015 181

Pulmonary Hypertension-Dormant Projects, H1 2015 212

Pulmonary Hypertension-Dormant Projects (Contd..1), H1 2015 213

Pulmonary Hypertension-Dormant Projects (Contd..2), H1 2015 214

Pulmonary Hypertension-Discontinued Products, H1 2015 215

List of Figures

Number of Products under Development for Pulmonary Hypertension, H1 2015 15

Number of Products under Development for Pulmonary Hypertension-Comparative Analysis, H1 2015 16

Number of Products under Development by Companies, H1 2015 17

Number of Products under Investigation by Universities/Institutes, H1 2015 22

Comparative Analysis by Late Stage Development, H1 2015 23

Comparative Analysis by Clinical Stage Development, H1 2015 24

Comparative Analysis by Early Stage Products, H1 2015 25

Assessment by Monotherapy Products, H1 2015 76

Assessment by Combination Products, H1 2015 77

Number of Products by Top 10 Targets, H1 2015 78

Number of Products by Stage and Top 10 Targets, H1 2015 78

Number of Products by Top 10 Mechanism of Actions, H1 2015 82

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 82

Number of Products by Top 10 Routes of Administration, H1 2015 85

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 85

Number of Products by Top 10 Molecule Types, H1 2015 87

Number of Products by Stage and Top 10 Molecule Types, H1 2015 87

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Actelion Ltd

APT Therapeutics, Inc.

Arena Pharmaceuticals, Inc.

Asahi Kasei Pharma Corp.

Ascendis Pharma A/S

Bayer AG

Bial - Portela & Ca, S.A.

Biolab Sanus Farmaceutica Ltda.

Cardioxyl Pharmaceuticals, Inc.

Carolus Therapeutics, Inc.

Celladon Corporation

Celsion Corporation

Corridor Pharmaceuticals Inc.

Cytokinetics, Inc.

Eli Lilly and Company

Gilead Sciences, Inc.

HanAll Biopharma Co., Ltd.

Hanmi Pharmaceuticals, Co. Ltd.

Ikaria Inc.

Insmed Incorporated

Ironwood Pharmaceuticals, Inc.

Lacer, S.A.

Longevity Biotech, Inc

LTT Bio-Pharma Co., Ltd.

Mast Therapeutics, Inc.

Mezzion Pharma Co. Ltd.

miRagen Therapeutics, Inc.

Nippon Shinyaku Co., Ltd.

Novartis AG

PharmaIN Corporation

PhaseBio Pharmaceuticals, Inc.

Pluristem Therapeutics Inc.

Proteo, Inc.

Reata Pharmaceuticals, Inc.

RegeneRx Biopharmaceuticals, Inc.

Sagene Pharmaceuticals, Inc.

Silence Therapeutics plc

Sinoxa Pharma GmbH

Suda Ltd

Therametrics holding AG

Toray Industries, Inc.

United Therapeutics Corporation

Vectura Group plc

Vicore Pharma AB

Pulmonary Hypertension Therapeutic Products under Development, Key Players in Pulmonary Hypertension Therapeutics, Pulmonary Hypertension Pipeline Overview, Pulmonary Hypertension Pipeline, Pulmonary Hypertension Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com